Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Drug Metabolism And Disposition

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.110.034561PMID 20702772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ketoconazole: A Review of its Therapeutic Efficacy in Superficial and Systemic Fungal Infections

  2012cited by this paper
• The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.

  2009cited by this paper
• Effect of Oral Ketoconazole on Oral and Intravenous Pharmacokinetics of Simvastatin and Its Acid in Cynomolgus Monkeys

  2009cited by this paper
• Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats

  2008cited by this paper
• Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

  2008cited by this paper
• Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.

  2008cited by this paper
• Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

  2007cited by this paper
• Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys

  2007cited by this paper
• Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey

  2007cited by this paper
• Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?

  2007cited by this paper
• Prediction of intestinal first-pass drug metabolism.

  2007cited by this paper
• Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

  2007cited by this paper
• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model

  2006cited by this paper
• Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans

  2006cited by this paper
• Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities.

  2005cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

  2003cited by this paper
• Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data.

  2002cited by this paper
• Cytochromes P450 and experimental models of drug metabolism

  2002cited by this paper
• Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site

  2000cited by this paper
• Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

  2000cited by this paper
• Molecular and physical mechanisms of first-pass extraction.

  1999cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• Grapefruit juice increases oral nimodipine bioavailability.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans

  1997cited by this paper
• Interaction between grapefruit juice and midazolam in humans

  1995cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects.

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450.

  1992cited by this paper
• Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time

  1992cited by this paper
• Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans

  1991cited by this paper
• Absolute Bioavailability of Carbamazepine After Oral Administration of a 2% Syrup

  1990cited by this paper
• Quantitation of extrahepatic metabolism. Pulmonary and intestinal conjugation of naphthol.

  1985cited by this paper
• Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat.

  1985cited by this paper
• Diazepam disposition determinants

  1980cited by this paper

• Separate Evaluation of Fraction Absorbed and Intestinal Availability after Oral Administration of Drugs Based on the Measurement of Portal and Systemic Plasma Concentrations and Luminal Concentration.

  2023cites this paper
• Extent and rate of oral drug absorption in minipigs: Comparison with mice, rats and humans

  2020cites this paper
• The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions

  2020cites this paper
• A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys

  2019cites this paper
• High Expression of UGT1A1/1A6 in Monkey Small Intestine: Comparison of Protein Expression Levels of Cytochromes P450, UDP-Glucuronosyltransferases, and Transporters in Small Intestine of Cynomolgus Monkey and Human.

  2018cites this paper
• Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance

  2018cites this paper
• Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound

  2017cites this paper
• In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.

  2017cites this paper
• Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic

  2017cites this paper
• Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

  2017cites this paper
• Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans

  2016cites this paper
• Species Differences in the Pharmacokinetic Parameters of Cytochrome P450 Probe Substrates between Experimental Animals, such as Mice, Rats, Dogs, Monkeys, and Microminipigs, and Humans

  2015cites this paper
• The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib

  2015cites this paper
• Quantitative Assessment of Intestinal First-pass Metabolism of Oral Drugs Using Portal-vein Cannulated Rats

  2015cites this paper
• Enhanced methamphetamine metabolism in rhesus macaque as compared to human: An analysis using a novel LCMS/MS method, kinetic study, and substrate docking

  2014cites this paper
• Enhanced Methamphetamine Metabolism in Rhesus Macaque as Compared with Human: An Analysis Using a Novel Method of Liquid Chromatography with Tandem Mass Spectrometry, Kinetic Study, and Substrate Docking

  2014cites this paper
• Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs

  2013cites this paper
• DMD054031 1975..1993

  2013cites this paper
• Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

  2013cites this paper
• Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach.

  2013cites this paper
• Contribution of rat intestinal metabolism to the xenobiotics clearance

  2013cites this paper
• Significance of Reductive Metabolism in Human Intestine and Quantitative Prediction of Intestinal First-Pass Metabolism by Cytosolic Reductive Enzymes

  2013cites this paper
• A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development

  2013cites this paper
• Extrahepatic Drug-Metabolizing Enzymes and Their Significance

  2012cites this paper
• Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability

  2012cites this paper
• Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.

  2012cites this paper
• Topics on Drug Metabolism

  2012cites this paper
• Theoretical Framework III: Biological Membrane Permeation

  2012cites this paper
• Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

  2012cites this paper
• In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

  2011influential citation
• Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

  2011cites this paper
• Species Differences in Distribution and Prediction of Human Vss from Preclinical Data

  2011cites this paper
• Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.

  2011cites this paper
• Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.

  2011cites this paper
• Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.

  2011cites this paper
• Role of intestinal transporters and metabolism in the oral absorption of drug and prodrugs.

  2010cites this paper